 TELA Bio Inc NASDAQ: TELA has launched its second post-market study, BRAVO II, to evaluate the clinical performance of OviTex Reinforced Tissue Matrices in the robotic repair of ventral hernias. The study will enroll up to 100 subjects with patient follow-up at 90 days, 12 months, and 24 months. 